Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and Jiangsu Vanguard Pharmaceutical Co., Ltd. entered into a co-development agreement for the ABA001 project, a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) mRNA. Vanguard will invest RMB 50 million (≈ US$7 million) in this phase, and both parties will jointly advance the clinical development, regulatory filing, and commercialization of ABA001 — a candidate positioned as a mechanistic breakthrough in hypertension management that suppresses the pressor effect of the renin-angiotensin-aldosterone system (RAAS) at its origin.
Deal Milestone
| Item | Detail |
|---|---|
| Parties | Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and Jiangsu Vanguard Pharmaceutical Co., Ltd. |
| Agreement Type | Co-development agreement |
| Asset | ABA001 – GalNAc-conjugated siRNA targeting AGT mRNA |
| Therapeutic Area | Hypertension (RAAS pathway) |
| Phase Investment | RMB 50 million (≈ US$7 million) from Vanguard |
| Scope | Joint clinical development, regulatory filing, and commercialization |
| Announcement Date | 24 Sep 2026 |
| Further Financial Terms | Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: ABA001, a small interfering RNA (siRNA) therapeutic.
- Target: Angiotensinogen (AGT) mRNA — the precursor protein of the entire RAAS cascade.
- Mechanism: By silencing AGT mRNA and blocking AGT protein synthesis, ABA001 suppresses the pressor effect of the RAAS at its origin — upstream of renin, angiotensin-converting enzyme, and the angiotensin II receptor.
- Therapeutic Concept: A departure from the symptomatic treatment approach of traditional antihypertensive agents (e.g., ACE inhibitors, ARBs, calcium-channel blockers, and diuretics, which require daily dosing and act downstream or on secondary mechanisms), representing a mechanistic breakthrough in hypertension management.
- Delivery Platform: GalNAc covalent conjugation delivery system, enabling efficient and targeted delivery of siRNA molecules specifically to liver cells (hepatocytes) — the site of AGT synthesis — thereby enhancing drug targeting and bioavailability.
- Development Stage of ABA001: Not disclosed.
Class Validation – The AGT siRNA Pathway
- International Frontier Alignment: The GalNAc–siRNA technological pathway aligns with international frontiers in cardiometabolic drug development.
- Peer Clinical Proof: Clinical studies of Zilebesiran, a peer siRNA drug in the same class, have demonstrated the efficacy and safety of this mechanism, showing that a single administration can sustain therapeutic effects for approximately 24 weeks.
- Implication for Hypertension Care: If sustained AGT silencing translates to durable blood-pressure control, infrequent dosing could address the adherence burden that undermines long-term management with daily oral antihypertensives.
- GalNAc Platform Maturity: GalNAc conjugation is an established hepatocyte-targeting approach already validated by approved siRNA medicines, supporting the translational rationale for ABA001’s design.
Market Impact & Outlook
- Shared-Risk Development Model: Vanguard’s RMB 50 million phase investment and the joint structure across clinical development, regulatory filing, and commercialization signal a shared-economics partnership rather than a straight asset license.
- China’s siRNA Momentum: The agreement adds to the growing wave of Chinese RNAi programs targeting cardiometabolic disease, with AGT among the most actively pursued hypertension targets globally.
- Large Addressable Population: Hypertension affects a vast patient population in China, and adherence-limited daily therapy leaves substantial room for long-acting, infrequently dosed alternatives.
- Competitive Landscape: ABA001 would compete in the emerging long-acting antihypertensive class alongside international AGT-silencing programs such as Zilebesiran; differentiation will depend on ABA001’s own clinical profile, which was not disclosed.
- Next Steps: Joint execution of clinical development and regulatory filing plans; trial design, timelines, and milestone-linked payment structures were not detailed in the announcement.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the co-development of ABA001 by Sun‑Novo and Vanguard Pharmaceutical, including expectations for clinical development, regulatory filing, commercialization, and the sustained blood-pressure-control potential of AGT silencing. Actual results may differ due to risks including clinical trial outcomes, regulatory review, manufacturing and delivery-platform scale-up, competitive dynamics, and the absence of disclosed development timelines. Class-level data cited for Zilebesiran pertain to a peer program and are not results of ABA001.-Fineline Info & Tech
